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Abstract
Background: Human Heat Shock Protein 60 (hHSP60) has been implicated in autoimmunity
through molecular mimicry, based on the high degree of homology with HSP65 of micro-organisms
leading to autoimmune recognition of the human protein. Additionally, sequence homology
between hHSP60 and myeloperoxidase (MPO) has been described. MPO is a major autoantigen in
vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA). We hypothesized that
infections may trigger the ANCA response against MPO through hHSP60.
Methods: In 86 consecutive patients with ANCA-associated vasculitis (AAV), anti-hHSP60 and
anti-mycobacterial HSP65 were measured by ELISA. Patients were compared with 69 healthy
controls (HC). Continuous data between groups were compared using Wilcoxon signed rank test
and Kruskal-Wallis test with Dunn's post-test when appropriate. Correlations between data were
derived using Spearman correlation. Odds ratios and 95% confidence intervals were obtained using
Fisher's exact test.
Results: At diagnosis, median anti-mHSP65 level was higher in AAV (median [range]: 42.5 [0–
500]), and subsequently in MPO-ANCA (44 [7–500]), compared to HC (22 [0–430]). Anti-hHSP60
levels in AAV were not higher compared to HC (18 [0–319] and 18.5 [0–98], respectively).
However, in MPO-ANCA anti-hHSP60 levels were increased (32.5 [0–319]) compared to PR3-
ANCA (13 [0–79]) and HC. We could not detect cross-reactivity between hHSP60 and MPO-
ANCA. There was a correlation between anti-mHSP65 and anti-hHSP60 levels (r = 0.32, P = 0.003)
but not between anti-hHSP60 and MPO-ANCA (r = -0.064, P = 0.69).
Conclusion: Antibodies against mHSP65 are higher in AAV compared to HC, and anti-hHSP60
antibodies are higher in patients with MPO-ANCA than in patients with PR3-ANCA and HC.
Although this finding may be indicative for cross-reactivity between MPO-ANCA and hHSP60,
additional assays did not support this hypothesis.
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Introduction
Small vessel vasculitides, such as Wegener's granulomato-
sis (WG) and microscopic polyangiitis (MPA), are
strongly associated with antineutrophil cytoplasmic anti-
bodies (ANCA), which are either directed to myeloperox-
idase (MPO) or proteinase 3 (PR3) [1-3]. These diseases
can occur in any organ system but the respiratory tract and
the kidneys are most frequently involved. Untreated, WG
results in death within weeks to months. Since the intro-
duction of cyclophosphamide and prednisolone as stand-
ard treatment, survival has improved dramatically from
less than 20% at 1 year reported in 1958 [4] to at least
60% 5-years survival reported in the past ten years [5-8].
The mechanism by which ANCA are induced is as yet
unclear. Certain drugs have been linked to the induction
of ANCA and the onset of ANCA-associated vasculitis
(AAV) [9]. Recently, it has been described that an autoim-
mune response may be induced by the presence of a pep-
tide that is antisense or complementary to the
autoantigen, for instance, PR3 [10]. This immune
response may induce anti-idiotypic antibodies (autoanti-
bodies) that cross-react with the autoantigen. Another
favored hypothesis is that infections may trigger an ANCA
response [11]. The proposed mechanisms by which infec-
tions break self tolerance can include bystander damage,
unveiling of 'hidden' self epitopes, determinant molecular
spreading and molecular mimicry [11].
Heat Shock Protein (HSP) 65 is an immunodominant
antigen in micro-organisms, and has already been impli-
cated in the pathogenesis of vasculitides such as Kawasaki
disease [12] and Behcet disease [13]. The human equiva-
lent, hHSP60, has been implicated in autoimmunity
through molecular mimicry, based on the high degree of
homology with HSP65 of micro-organisms leading to
autoimmune recognition of the human protein [14]. In its
turn, HSP60 shares sequence homology with MPO [15].
Thus, infections may trigger the ANCA response against
MPO through hHSP60. To test this hypothesis, we deter-
mined the presence of antibodies against hHSP60 and
mycobacterial HSP65 (mHSP65) in patients with MPO-
ANCA and compared them to patients with PR3-ANCA
and healthy controls (HC). Results showed that antibod-
ies against mHSP65 are higher in AAV compared to HC,
and anti-hHSP60 antibodies are higher in patients with
MPO-ANCA than in patients with PR3-ANCA and HC.
However, additional assays did not support our hypo-
thesis of cross-reactivity between MPO-ANCA and
hHSP60.
Methods
Patients
We retrospectively identified all patients in our renal
biopsy registry [16,17] diagnosed with crescentic glomer-
ulonephritis between January 1977 and July 2003 without
evidence of systemic lupus erythematosus, IgA nephropa-
thy, Henoch Schönlein purpura, post-infectious glomeru-
lonephritis or cryoglobulinaemia. Serum samples, taken
at the time of biopsy, were tested for the presence of
ANCA, according to a multistep procedure that combines
indirect immunofluorescence with direct and capture
enzyme-linked immunosorbent assays (ELISAs) [18]. We
thus identified 109 patients with AAV with biopsy-proven
renal involvement: 46 patients with PR3-ANCA only
(42%), 49 patients with MPO-ANCA only (45%), 4
patients with both PR3- and MPO-ANCA (4%) and 10
patients with MPO-ANCA with the presence of anti-
glomerular basement membrane antibodies (9%). Only
patients who were single positive for PR3- or MPO-ANCA,
and had enough serum available for all tests, were
included (n = 86). Additionally, 40 healthy controls (HC)
(laboratory personnel) were tested to determine the cut-
off value for the anti-hHSP60 test and, 69 HC were tested
to determine the cut-off value for the anti-mHSP65 test.
This study was performed in accordance with the 1997
Declaration of Helsinki of the World Medical Association.
Demographic data on patients and controls are presented
in table 1.
Sera
Serum samples, taken at the time of biopsy, were used to
determine the presence of anti-hHSP60 and anti-mHSP65
in patients with AAV. These sera had been stored at -80°C,
in some patients for over 20 years. However, when testing
the antibody response, there was no difference in anti-
body level between patients included in 2003 and
patients included in earlier years.
Table 1: Demographic data on patients and healthy controls
AAV (N = 86) MPO-ANCA (N = 42) PR3-ANCA (N = 44) HC (N = 69)
Age (years)* 62.2 ± 13.5 65.9 ± 10.9 59.7 ± 15.2 40.4 ± 9.8
Male gender (%) 69 64 73 59
AAV, ANCA-associated vasculitis; MPO-ANCA, antineutrophil cytoplasmic antibodies against myeloperoxidase; PR3-ANCA, ANCA against proteinase 3; HC, 
healthy controls
* Mean ± standard deviationJournal of Autoimmune Diseases 2006, 3:4 http://www.jautoimdis.com/content/3/1/4
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ELISA for the detection of antibodies against human 
HSP60 and mycobacterial HSP65
Recombinant hHSP60 (Stressgen, Victoria, Canada) was
diluted to 2 μg/mL in coating buffer containing 0.1 M
NaHCO3
- (pH 9.6), and 50 μL/well (i.e., 0.1 μg/well) was
incubated in wells of microplates (Nunc MaxiSorp™,
Rochester, NY) overnight at 4°C. Control wells were incu-
bated with coating buffer alone. Wells were then incu-
bated overnight at 4°C with 100 μL/well coating buffer
containing 1% grade V bovine serum albumin (BSA,
Sigma, St. Louis, MO) to block non-specific binding.
Plates were then washed 3 times with PBS containing
0.05% Tween 20 (PBS-T). Plates were preincubated at
room temperature with 200 μL/well of preincubation
buffer, containing 0.05% Tween 20 and 1% BSA in PBS,
for 1 hour. After washing 2 times with PBS-T, wells were
incubated in triplicates with patient serum in a previously
established optimal dilution of 1:50, 50 μL/well, in incu-
bation buffer and kept overnight at 4°C. The next day,
plates were washed 5 times with PBS-T and incubated
with goat F(ab')2 anti-human IgG (Fc)-horseradish perox-
idase conjugate (Cappel-ICN Immunobiologicals, Costa
Mesa, CA), diluted 1:2000 in incubation buffer, for 2
hours at room temperature. After washing 5 times with
PBS-T, 100 μL of freshly made substrate (containing 0.5
mg/mL o-Phenylenediamine (Sigma) and 0.03% H2O2 in
citrate/phosphate buffer, pH 4.9) was added to each well.
After 10 minutes, the reaction was stopped with 50 μL 4N
H2SO4 and absorbances were read at 490 nm. Results are
expressed as anti-hHSP60 levels in arbitrary units (AU)/
mL. Hereto, the mean OD of the triplicates was corrected
for non-specific binding by subtraction of the mean OD
in uncoated wells. Next, a standard curve was created by
including in every assay a serial, 2-step dilution from 1:10
to 1:640 of a positive serum sample with anti-hHSP60
reactivity. The undiluted serum sample was arbitrarily
assigned 100 AU/mL. Additionally, results are expressed
as positive or negative. To establish the cut-off value for
this test, the mean AU/mL and SD of the sera of 40 HC
were determined, and the cut-off value was set at the mean
+ 2 SD.
For detection of antibodies against mHSP65, essentially
the same procedure was followed. Recombinant mHSP65
(Stressgen) was diluted to 2 μg/mL and coated in a con-
centration of 0.1 μg/well. Serum was diluted 1:50 prior to
incubation. To read results in AU, a standard curve was
created as described for anti-hHSP60 antibodies. To estab-
lish the cut-off value for this test, the mean AU/mL and SD
of the sera of 69 HC were determined, and the cut-off
value was set at the mean + 2 SD.
Myeloperoxidase inhibition assays
To test cross-reactivity between MPO and hHSP60, serum
from one patient being positive for both MPO-ANCA and
anti-hHSP60 antibodies was incubated for 30 minutes at
37°C with MPO or hHSP60 in concentrations of 1, 3, 10
and 20 μg/mL. The serum was then tested in the anti-
hHSP60 ELISA as described above, or in the MPO-ANCA
ELISA using commercially available direct ELISA kits
(Euro-diagnostica, Malmö, Sweden). Additionally,
absorption tests were performed in which ELISA plates
were coated with hHSP60 or MPO and incubated with
serum. The next day, or the second day, anti-hHSP60 reac-
tivity in this pre-absorbed serum was tested as described
above for the anti-hHSP60 ELISA. Unfortunately, this was
the only patient of whom enough serum was present to
perform the described tests.
Statistical analyses
All data are presented as median [range] unless stated oth-
erwise. Continuous data between groups were compared
using Wilcoxon signed rank test and Kruskal-Wallis test
with Dunn's post-test when appropriate. Due to the per-
ceived relevance of the results, we did not only perform
Dunn's post-test for subgroup analysis, but we also com-
pared subgroups using Wilcoxon signed rank test. Corre-
lations between data were derived using Spearman
correlation. Odds ratios (OR) and 95% confidence inter-
vals (CI) were obtained using Fisher's exact test. Analyses
were performed with GraphPad Prism version 3.00 and
GraphPad Instat software package version 2.04a (both
GraphPad Software Inc., San Diego, CA). A two-sided p-
value < 0.05 was considered to indicate statistical signifi-
cance.
Results
Eighty-six consecutive patients with AAV (44 PR3- and 42
MPO-ANCA) were included in the study. Mean age was
62.2 ± standard deviation 13.5 (65.9 ± 10.9 in MPO-
ANCA and 59.7 ± 15.2 in PR3-ANCA, P = 0.07). Fifty-nine
patients (69%) were male (27 patients (64%) in MPO-
ANCA and 32 patients (73%) in PR3-ANCA, P = 0.49).
Anti-mycobacterial HSP65 antibodies are elevated in 
MPO-ANCA compared to healthy controls
In patients with AAV, median anti-mHSP65 level was 42.5
AU/mL [0–500], compared to 22 AU/mL [0–430] in
healthy controls (P = 0.008, figure 1). In MPO-ANCA,
antibody levels were significantly higher (44 AU [7–500])
compared to HC (P = 0.006, figure 1). In patients with
PR3-ANCA, there was a trend to a higher antibody level
(42.5 AU [0–500] compared to HC (P = 0.10). With a cut-
off value of 88.5 AU/mL, 13 of 69 HC (19%) were positive
for anti-mHSP65 compared to 23 of 86 (27%) patients
with AAV (P = NS). Eleven of 44 (25%) patients with PR3-
ANCA were positive for anti-mHSP65 compared to 12 of
42 patients with MPO-ANCA (29%) (P = NS). Next, we
confirmed the specificity of the anti-mHSP65 antibodies
by immunoblotting. To this end we selected 5 sera thatJournal of Autoimmune Diseases 2006, 3:4 http://www.jautoimdis.com/content/3/1/4
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were positive by ELISA. All sera reacted with a 65 kD band
in an immunoblot with recombinant mHSP65 (data not
shown).
Anti-human HSP60 antibodies are elevated in MPO-ANCA 
compared to PR3-ANCA and healthy controls
In patients with AAV, median anti-hHSP60 level was 18
AU/mL [0–319], compared to 18.5 AU/mL [0–98] in
healthy controls (P = NS, figure 2). In MPO-ANCA, anti-
body levels were significantly higher (32.5 AU [0–319])
compared to HC (P = 0.02) and PR3-ANCA (13 AU [0–
79]) (P < 0.0001, figure 2). Patients with PR3-ANCA did
not have higher antibody levels than HC. With a cut-off
value of 80 AU/mL, 2 of 40 HC (5%) were positive for
anti-hHSP60 compared to 12 of 86 (14%) patients with
AAV (P = NS). One of 44 (2.3%) patients with PR3-ANCA
was positive for anti-hHSP60 compared to 11 of 42
patients with MPO-ANCA (26%) (P = 0.001, OR 15.3,
95% CI 1.9 – 124). Next, we confirmed the specificity of
the anti-hHSP60 antibodies by immunoblotting. To this
end we selected 5 sera that were positive by ELISA. All sera
reacted with a 60 kD band in an immunoblot with recom-
binant hHSP60 as well as with native bovine HSP60. The
latter indicates that the antigenicity of recombinant and
native HSP60 compares well (data not shown).
Myeloperoxidase does not inhibit anti-hHSP60 antibody 
reactivity
To test whether anti-hHSP60 antibodies actually cross-
react with MPO, we performed inhibition assays incubat-
ing serum from the patient with the highest anti-hHSP60
response with MPO or hHSP60 and testing for hHSP60
and MPO reactivity. Incubation with increasing concen-
trations of MPO inhibited the MPO-ANCA response in a
dose-dependent manner (figure 3A). However, incuba-
tion of serum with hHSP60 did not inhibit the MPO-
ANCA reactivity (figure 3A). Additionally, MPO was una-
ble to inhibit the anti-hHSP60 antibody reactivity (figure
3B). However, incubation with hHSP60 did not inhibit
the anti-hHSP60 response (figure 3B). To test for the abil-
ity of hHSP60 to inhibit anti-hHSP60 reactivity, absorp-
tion tests were performed. Results now showed inhibition
of the anti-hHSP60 response by hHSP60 but not by MPO
(figure 4).
Follow-up anti-hHSP60 levels
To further exclude cross-reactivity between hHSP60 and
MPO-ANCA, we tested whether anti-hHSP60 antibody
levels were only present if there was presence of MPO-
ANCA. In the patient with MPO-ANCA and the highest
anti-hHSP60 level, follow-up serum samples were availa-
Anti-hHSP60 antibody levels in healthy controls (HC) and in  patients with ANCA-associated vasculitis (AAV) Figure 2
Anti-hHSP60 antibody levels in healthy controls (HC) and in 
patients with ANCA-associated vasculitis (AAV). Anti-human 
Heat Shock Protein 60 (anti-hHSP60) antibody levels are not 
significantly higher in AAV compared to HC (18 AU/mL [0–
319] and 18.5 AU [0–98], respectively). Furthermore, anti-
hHSP60 antibody levels in patients with PR3- and MPO-
ANCA. Anti-hHSP60 are significantly higher in patients with 
MPO-ANCA compared to PR3-ANCA (32.5 AU [0–319], 
and 13 AU [0–79], respectively). In patients with MPO-
ANCA, anti-hHSP60 antibody level is also significantly higher 
when compared to HC (P = 0.02), whereas in PR3-ANCA, it 
is not. Dotted line represents cut-off value; solid line repre-
sents median value.
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Anti-mHSP65 antibody levels in healthy controls (HC) and in  patients with ANCA-associated vasculitis (AAV) Figure 1
Anti-mHSP65 antibody levels in healthy controls (HC) and in 
patients with ANCA-associated vasculitis (AAV). Anti-myco-
bacterial Heat Shock Protein 65 (anti-mHSP65) antibody lev-
els are significantly higher in AAV compared to HC (42.5 AU/
mL [0–500] and 22 AU [0–430], respectively). Furthermore, 
anti-mHSP65 antibody levels in patients with PR3- and MPO-
ANCA are shown. Anti-mHSP65 is comparable between 
patients with MPO-ANCA and PR3-ANCA (44 AU [7–500], 
and 42.5 AU [0–500], respectively). In patients with MPO-
ANCA, anti-mHSP65 antibody level is significantly higher 
when compared to HC (P = 0.006). Dotted line represents 
cut-off value; solid line represents median value.
cut-off
ANCA HC MPO-ANCA PR3-ANCA
0
200
400
600
cut-off
p = 0.008
p = 0.006
Study group
a
n
t
i
-
m
H
S
P
6
5
 
(
A
U
/
m
L
)Journal of Autoimmune Diseases 2006, 3:4 http://www.jautoimdis.com/content/3/1/4
Page 5 of 7
(page number not for citation purposes)
ble to test for the presence of anti-hHSP60. As shown in
figure 5, anti-hHSP60 levels dropped analogous to MPO-
ANCA levels once treatment has commenced, but slightly
increased with tapering of the treatment while MPO-
ANCA levels remained undetectable.
Correlation between anti-mHSP65 and anti-hHSP60 but 
not between MPO-ANCA and anti-hHSP60 antibodies
Finally, we checked whether correlation exists between
antibody levels against mHSP65, hHSP60, and MPO.
There was a correlation between height of antibody levels
against mHSP65 and hHSP60 (Spearman r = 0.32, P =
0.003), but no correlation existed between MPO-ANCA
and anti-hHSP60 (Spearman r = -0.064, P = 0.69). Also,
there was no correlation between anti-mHSP65 and
MPO-ANCA (Spearman r = 0.074, P = 0.65).
Discussion
The mechanism by which ANCA are induced are as yet
unclear. One favored hypothesis is that infections may
trigger an ANCA response [11]. We hypothesized that
infections may trigger the ANCA response against MPO
through hHSP60. We found that anti-hHSP60 was almost
exclusively found among patients with MPO-ANCA when
compared to PR3-ANCA, supporting our hypothesis. Nev-
ertheless, there was no correlation between MPO-ANCA
and anti-hHSP60 antibody levels, and inhibition and
absorption assays did not show cross-reactivity between
hHSP60 and MPO-ANCA. Furthermore, when we deter-
mined the anti-mHSP65 response in AAV and HC, we
found no difference between patients with MPO-ANCA
and patients with PR3-ANCA, and only a weak correlation
between anti-hHSP60 antibody levels and anti-mHSP65
levels. However, not every patient who was positive for
anti-hHSP60 had antibodies against mHSP65, suggesting
that anti-hHSP60 and anti-mHSP65 are not the same anti-
bodies, and that an anti-hHSP60 response may not be
triggered simultaneously with an anti-mHSP65 response.
Increased anti-HSP antibody levels, as observed in the
present study, might be artificial because of two reasons.
First, patients with several systemic autoimmune diseases
are known to have increased levels of circulating IgG and
MPO and hHSP60 absorption assays Figure 4
MPO and hHSP60 absorption assays. Incubation of serum in 
ELISA plates coated with human Heat Shock Protein 60 
(hHSP60) for 1 or 2 days leads to a reduction in anti-hHSP60 
reactivity (●). In contrast, incubation of serum in ELISA 
plates coated with myeloperoxidase (MPO) does not 
decrease anti-hHSP60 reactivity (■).
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MPO-ANCA inhibition assay Figure 3
Upper panel: (3A) MPO-ANCA inhibition assay. Incubation 
with increasing concentrations of myeloperoxidase (MPO) (1 
– 20 μg/mL) leads to a reduction in MPO-ANCA reactivity 
(■). In contrast, incubation with human Heat Shock Protein 
60 (hHSP60) (1 – 20 μg/mL) does not decrease MPO-ANCA 
reactivity (●). Lower panel: (3B) Anti-human Heat Shock 
Protein 60 (hHSP60) inhibition assay. Incubation with 
increasing concentrations of myeloperoxidase (MPO) (1 – 20 
μg/mL) does not lead to a reduction in anti-hHSP60 reactivity 
(■). However, incubation with hHSP60 (1 – 20 μg/mL) only 
slightly decreases anti-hHSP60 reactivity (●)
1 3 10 20
0
20
40
60
80
100
120
concentration (ug MPO or hHSP60)
M
P
O
-
A
N
C
A
 
(
A
U
/
m
L
)
1 3 10 20
0.0
0.4
0.8
1.2
1.6
concentration (ug MPO or hHSP60/mL)
a
n
t
i
-
h
H
S
P
6
0
 
(
A
U
/
m
L
)Journal of Autoimmune Diseases 2006, 3:4 http://www.jautoimdis.com/content/3/1/4
Page 6 of 7
(page number not for citation purposes)
this might result in a simultaneous increase in antibodies
to, for instance, HSP60 and HSP65. Although analysis of
IgG levels is not a standard procedure for the diagnostic
work-up of an AAV patient, IgG data were available for a
subset of patients included and all were within the normal
range (data not shown). Furthermore, to our knowledge
such hypergammaglobulinaemia has not been described
for AAV. Second, since healthy controls in the current
study were of lower age than the AAV patients, increased
levels of antibodies to HSP60 and HSP65 might be due to
ageing. Again this is not very likely since there was no cor-
relation whatsoever (R2 < 0.1) between antibody titers and
age (data not shown). Therefore we conclude that anti-
body levels to HSP60 and HSP65 are really increased in
AAV patients as compared to healthy controls.
The shared sequence homology described between
hHSP60 and MPO is a theoretical one, based on amino
acid sequence. This sequence similarity has a length of 17
amino acids and is present on the heavy chain of mye-
loperoxidase [15]. The sequence is present in a region of
myeloperoxidase that is recognized as an epitope by
MPO-ANCA in some patients [19]. However, it is
unknown whether anti-hHSP60 antibodies bind to the
corresponding amino acid sequence of hHSP60. To test
whether anti-hHSP60 antibodies actually cross-react with
MPO, we performed inhibition assays incubating serum
from the patient with the highest anti-hHSP60 response
with MPO or hHSP60 and testing for hHSP60 and MPO
reactivity. We could not detect a decrease in hHSP60 reac-
tivity when serum was incubated with MPO, suggesting
that although sequence homology exists, epitopes recog-
nized by MPO-ANCA are different from those recognized
by anti-hHSP60 antibodies. Obviously, this test cannot
completely exclude that cross-reactivity exists in other
patients, although the absence of correlation between
MPO-ANCA and anti-hHSP60 also does not support such
cross-reactivity.
Antibodies against hHSP60 are associated with the pres-
ence and severity of atherosclerosis [20-22], although this
has been disputed by others [23]. Interestingly, we found
elevated levels of anti-hHSP60 antibodies only in patients
with MPO-ANCA. An explanation for this finding may be
that diagnosis of MPO-AAV is often delayed, and this may
lead to prolonged inflammation and eventually to ele-
vated levels of anti-hHSP60 in MPO-ANCA patients when
compared to PR3-ANCA patients. Our data might indicate
that cardiovascular disease is more often present in
patients with MPO-ANCA. However, follow-up data in
our small study do not confirm this.
Interestingly, anti-hHSP60 reactivity could not be inhib-
ited by our first inhibition assay. This may be due to the
nature of the inhibition assay. In the first assay, hHSP60
was added to the serum of the anti-hHSP60 positive
patient, whereas in the second assay, hHSP60 was coated
to the ELISA plate. This second assay clearly demonstrated
inhibition of the anti-hHSP60 response. An explanation
for this phenomenon may be that anti-hHSP60 antibod-
ies are unable to bind to fluid phase hHSP60, but can
bind to solid phase hHSP60, as demonstrated by the sec-
ond inhibition assay, and the positive antibody response
demonstrated in the anti-hHSP60 ELISA.
Conclusion
We have shown that antibodies against hHSP60 are ele-
vated in patients with MPO-ANCA in comparison with
PR3-ANCA. These findings suggest a role for infections in
the pathogenesis of MPO-AAV through molecular mim-
icry between bacterial HSP65, human HSP60 and MPO.
Additional absorption assays, however, did not support
this hypothesis. Whether there is a relationship between
anti-hHSP60 and cardiovascular disease in patients with
MPO-ANCA remains to be studied.
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